Jasper Therapeutics is enabling cures through stem cell transplantation. The company is testing a c-Kit/ CD119 antibody (JSP-191) which is currently in late-stage clinical testing for Hematopoietic Cell Transplantation (HCT) associated with Severe Combined Immunodeficiency and MDS/AML. The humanized monoclonal antibody creates a niche space in the bone marrow by safely and specifically targeting and depleting blood forming stem cells and progenitor cells. Jasper intends to license JSP-191 for gene and cell therapy preconditioning regimes. Jasper was founded out of Stanford and JSP-191 was invented and developed at Amgen.

LocationCalifornia, US
CEOWilliam Lis
Partner Kurt von Emster
Websitewww.jaspertherapeutics.com